• Synthetic Lethality via WRN Inhibition in MMR-Deficient Colo

  2026-05-20

  This article reviews how the reference study uncovers the mechanism behind synthetic lethality in mismatch repair (MMR)-deficient colorectal cancer through Werner (WRN) helicase inhibition. The findings demonstrate that p53 and PUMA mediate apoptosis upon WRN loss, highlighting a precise vulnerability in p53-wildtype MSI CRCs and supporting the rationale for RecQ helicase inhibitors in translational oncology.

• SR-202 (PPAR antagonist): Accelerating Insulin Resistance Re

  2026-05-20

  SR-202 unlocks precision in dissecting PPARγ-driven metabolic and immunological pathways, setting a new benchmark for insulin resistance and obesity research. Its robust selectivity and translational relevance make it indispensable for both in vitro adipogenesis and in vivo metabolic disease models.

• PNU 74654: A Precise Wnt Signaling Pathway Inhibitor in Rese

  2026-05-19

  PNU 74654 delivers highly selective, reproducible inhibition of the Wnt/β-catenin pathway, enabling advanced dissection of cell proliferation and differentiation in cancer and stem cell research. This guide translates the latest mechanistic insights into actionable workflows and troubleshooting strategies for robust experimental success.

• Macrophage EP4 Deficiency Accelerates Atherosclerosis via CD

  2026-05-19

  This study demonstrates that loss of the prostaglandin E2 receptor EP4 in macrophages leads to exacerbated atherosclerosis by increasing CD36-mediated lipid uptake and promoting pro-inflammatory M1 macrophage polarization. The findings provide mechanistic insight into macrophage-driven plaque progression and highlight CD36 as a potential therapeutic target in cardiovascular disease.

• Hexetidine (NSC-17764): Redefining Oral Antimicrobial Strate

  2026-05-18

  This thought-leadership article explores the mechanistic, experimental, and translational dimensions of Hexetidine (NSC-17764), integrating data-driven insights from comparative studies and workflow optimization guides. Addressing the nuanced performance of Hexetidine in oral infection models, biofilm assays, and clinical settings, we provide actionable guidance for translational researchers seeking robust, evidence-backed workflows that advance beyond conventional product summaries.

• Puromycin dihydrochloride: Reliable Selection & Translationa

  2026-05-18

  This article dissects common laboratory challenges in cell viability and protein synthesis assays, demonstrating how Puromycin dihydrochloride (SKU B7587) ensures reproducible, data-driven outcomes. Integrating current literature and validated protocols, it guides researchers through solution-oriented scenarios—spanning concentration optimization to product selection—highlighting the compound's robust performance and practical workflow advantages.

• Epinephrine Bitartrate: Advancing Adrenergic Research Workfl

  2026-05-17

  Epinephrine Bitartrate (SKU B1358) from APExBIO empowers researchers with unmatched purity and solubility for adrenergic signaling studies. This article delivers a practical workflow, troubleshooting strategies, and evidence-based protocol enhancements to elevate cardiovascular and neurobiology research using this robust adrenergic receptor agonist.

• Fucoidan Mitigates Chemotherapy-Induced Steatohepatitis via

  2026-05-16

  This study demonstrates that Fucoidan, a sulfated α-L-fucan, alleviates irinotecan-induced steatohepatitis in mice by restoring intestinal barrier function and suppressing hepatic neutrophil extracellular trap formation. The findings provide mechanistic insight into the gut–liver axis as a therapeutic target for chemotherapy-associated liver injury.

• PKM2 Inhibitor (Compound 3k): Selective Glycolysis Disruptio

  2026-05-15

  PKM2 inhibitor (compound 3k) is a potent, selective pyruvate kinase M2 inhibitor that disrupts aerobic glycolysis in cancer and inflammatory cells. Its high selectivity and favorable in vivo profile position it as a leading antiproliferative agent for cancer research and a tool for immunometabolic studies.

• Meropenem Trihydrate: Mechanistic Leverage in Translational

  2026-05-15

  This thought-leadership article provides a deep dive into the mechanistic utility of Meropenem trihydrate in translational research on antimicrobial resistance (AMR). By integrating cutting-edge metabolomics, strategic workflow guidance, and competitive landscape analysis, it empowers researchers to decode resistance phenotypes and accelerate innovations in bacterial infection treatment.

• Bismuth Subsalicylate: Redefining Translational GI Research

  2026-05-14

  This thought-leadership article explores the advanced mechanistic and translational impact of Bismuth Subsalicylate (1,3,2λ2-benzodioxabismin-4-one) in gastrointestinal disorder research. Bridging membrane biology, inflammation modulation, and apoptosis detection, it offers strategic guidance for researchers aiming to expand beyond standard experimental paradigms.

• BMX Kinase and Lysosomal Acidification in Mtb Survival Mecha

  2026-05-14

  This study uncovers a mechanism by which Mycobacterium tuberculosis (Mtb) subverts host lysosomal acidification to enhance its intracellular survival, identifying BMX kinase-mediated phosphorylation of ATP6V1E1 as a central event. The findings highlight a potential therapeutic axis for host-directed interventions against tuberculosis.

• Antiplasmodial Aminopeptidase Inhibition: Insights from Pheb

  2026-05-13

  This article reviews the recent investigation of phebestin, a bestatin-related aminopeptidase inhibitor, as a promising antimalarial agent. The study elucidates phebestin's efficacy against multiple Plasmodium strains and its mechanistic parallels to bestatin, highlighting implications for targeted protease inhibition in infectious disease research.

• SR-202: Precision PPARγ Antagonism in Metabolic Research

  2026-05-13

  SR-202, a selective PPARγ antagonist, empowers researchers to dissect adipogenesis, macrophage polarization, and insulin resistance at a mechanistic level. Its high solubility, in vivo efficacy, and reproducibility make it a standout reagent for anti-obesity and type 2 diabetes research applications.

• Nadolol (SQ-11725): Translational Mastery in Cardiovascular

  2026-05-12

  This thought-leadership article explores how Nadolol (SQ-11725), a non-selective beta-adrenergic receptor blocker and OATP1A2 substrate, uniquely empowers translational cardiovascular research. Integrating mechanistic insights and evidence-based workflow guidance, we examine biological rationale, experimental best practices, and strategic considerations for hypertension, angina pectoris, and vascular headache models. Drawing on recent pharmacokinetic studies and APExBIO’s validated sourcing, we provide a roadmap for researchers seeking reproducibility and translational impact in the evolving landscape of cardiovascular therapeutics.

16106 records 1/1074 page Next 12345 下5页 Last page